MedElevator
Войти в исследования ESMO open · 2026
First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors.
СтатьяКлиническое исследование I фазыМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siu L L, Gutierrez M E, Pudelko L, Ruth K, Filho M A F N, Zaynagetdinov R, Hu P, Kitzing T, Guenhan B K, Durutovic I, McKean M
Аннотация
BACKGROUND: Adenosine is a key driver of an immunosuppressive tumor microenvironment. Elevated extracellular adenosine levels in the tumor microenvironment contribute to therapeutic resistance via A2A and A2B adenosine receptor signaling on T cells. Dual A2A/A2B antagonism may provide a therapeutic advantage compared with selective inhibition of either receptor alone. Muvadenant (M1069), a small molecule dual antagonist of A2A and A2B receptors, showed encouraging preclinical activity.
PATIENTS AND METHODS: This phase I, open-label, first-in-human study (NCT05198349) evaluated muvadenant in adult patients with advanced solid malignancies (Eastern Cooperative Oncology Group performance status ≤1). Primary objectives were determination of maximum tolerated dose and recommended dose for expansion of muvadenant. Additional objectives included pharmacokinetics, pharmacodynamics and early signs of efficacy.
RESULTS: Overall, 15 patients were evaluated across four dose levels (DLs) of muvadenant monotherapy provided twice daily (bd): 150 mg (n = 3), 300 mg (n = 3), 450 mg (n = 6), and 600 mg (n = 3). Dose-limiting toxicities were reported in two patients [grade 4 blood creatinine phosphokinase increased (450-mg DL, n = 1) and grade 3 lipase increased (600-mg DL, n = 1)]. Fatigue and nausea were the most common adverse events (n = 5 each, 33.3% each), while nausea was the most common muvadenant-related adverse event (n = 4, 26.7%). Two deaths were reported, both attributed to disease progression >30 days after treatment end. Best overall response of stable disease was recorded in three patients, including one patient with a stable disease of 12.6 months at the 150-mg DL. Median progression-free survival was 1.3 months (95% confidence interval 1.2-2.6). The potential recommended dose for expansion was 450-mg bd, and the maximum tolerated dose was not established due to early closure of the study.
CONCLUSIONS: Muvadenant was generally well tolerated; however, no antitumor activity was observed. A potential dose-response could not be determined due to limited number of patients per DL.
PATIENTS AND METHODS: This phase I, open-label, first-in-human study (NCT05198349) evaluated muvadenant in adult patients with advanced solid malignancies (Eastern Cooperative Oncology Group performance status ≤1). Primary objectives were determination of maximum tolerated dose and recommended dose for expansion of muvadenant. Additional objectives included pharmacokinetics, pharmacodynamics and early signs of efficacy.
RESULTS: Overall, 15 patients were evaluated across four dose levels (DLs) of muvadenant monotherapy provided twice daily (bd): 150 mg (n = 3), 300 mg (n = 3), 450 mg (n = 6), and 600 mg (n = 3). Dose-limiting toxicities were reported in two patients [grade 4 blood creatinine phosphokinase increased (450-mg DL, n = 1) and grade 3 lipase increased (600-mg DL, n = 1)]. Fatigue and nausea were the most common adverse events (n = 5 each, 33.3% each), while nausea was the most common muvadenant-related adverse event (n = 4, 26.7%). Two deaths were reported, both attributed to disease progression >30 days after treatment end. Best overall response of stable disease was recorded in three patients, including one patient with a stable disease of 12.6 months at the 150-mg DL. Median progression-free survival was 1.3 months (95% confidence interval 1.2-2.6). The potential recommended dose for expansion was 450-mg bd, and the maximum tolerated dose was not established due to early closure of the study.
CONCLUSIONS: Muvadenant was generally well tolerated; however, no antitumor activity was observed. A potential dose-response could not be determined due to limited number of patients per DL.